ATE199829T1 - Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon - Google Patents

Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon

Info

Publication number
ATE199829T1
ATE199829T1 AT95922166T AT95922166T ATE199829T1 AT E199829 T1 ATE199829 T1 AT E199829T1 AT 95922166 T AT95922166 T AT 95922166T AT 95922166 T AT95922166 T AT 95922166T AT E199829 T1 ATE199829 T1 AT E199829T1
Authority
AT
Austria
Prior art keywords
therapeutic
meta substituted
diagnostic use
substituted arylalkylamines
compounds
Prior art date
Application number
AT95922166T
Other languages
English (en)
Inventor
David R Elmaleh
Allan J Fischman
Original Assignee
Thejmde Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,512 external-priority patent/US6004990A/en
Application filed by Thejmde Trust filed Critical Thejmde Trust
Application granted granted Critical
Publication of ATE199829T1 publication Critical patent/ATE199829T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95922166T 1994-06-03 1995-06-02 Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon ATE199829T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25403294A 1994-06-03 1994-06-03
US08/265,512 US6004990A (en) 1994-06-03 1994-06-24 Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
PCT/US1995/006950 WO1995033455A1 (en) 1994-06-03 1995-06-02 Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof

Publications (1)

Publication Number Publication Date
ATE199829T1 true ATE199829T1 (de) 2001-04-15

Family

ID=26943786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922166T ATE199829T1 (de) 1994-06-03 1995-06-02 Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon

Country Status (13)

Country Link
US (2) US5587398A (de)
EP (1) EP0762877B1 (de)
JP (1) JP3839049B2 (de)
AT (1) ATE199829T1 (de)
AU (1) AU707142B2 (de)
CA (1) CA2191996A1 (de)
DE (1) DE69520430T2 (de)
DK (1) DK0762877T3 (de)
ES (1) ES2157330T3 (de)
GR (1) GR3036072T3 (de)
HK (1) HK1014671A1 (de)
PT (1) PT762877E (de)
WO (1) WO1995033455A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
SK13532000A3 (sk) * 1998-03-17 2002-07-02 Pfizer Products Inc. Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
CA2712256A1 (en) * 2008-01-18 2009-07-23 Allergan, Inc. Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
JP6774402B2 (ja) 2014-09-29 2020-10-21 ゾゲニクス インターナショナル リミテッド 薬物供給管理用の管理システム
EP3170807B1 (de) 2015-11-23 2019-12-11 Frau Pharma S.r.l. Neues verfahren zur synthese von fenfluramin
US20170174614A1 (en) * 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US10351509B2 (en) * 2015-12-22 2019-07-16 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
CA3032996A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (de) 2018-05-11 2021-03-17 Zogenix International Limited Zusammensetzungen und verfahren zur behandlung von plötzlichem tod infolge eines krampfanfalls
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6626M (de) * 1967-09-22 1969-01-13
DE1802297C3 (de) * 1967-10-25 1974-10-17 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt, Budapest Isopropylaminderivate und Verfahren zu ihrer Herstellung
US3573304A (en) * 1968-12-03 1971-03-30 Delalande Sa 1-dimethylamino - 3 - methyl-2(pyridyl or pyridazinyl) pentane and the corresponding non-toxic acid addition salts thereof
US3856857A (en) * 1970-02-13 1974-12-24 En Nom Collectif Science Union Amino acids and their derivatives
US3733339A (en) * 1970-10-05 1973-05-15 Abbott Lab Disubstituted propionamides
USB787097I5 (de) * 1971-06-04
BE791772A (fr) * 1971-06-11 1973-03-16 Buzas Andre Derives d'acides phenoxy-acetiques, leur preparation et leur application en therapeutique
BE795041A (fr) * 1972-02-07 1973-08-06 Science Union & Cie Nouveaux derives de l'amino-propane
GB1434088A (en) * 1973-08-16 1976-04-28 Science Union & Cie N-substituted glycinates a process for their preparation and pharmaceutical compositions containing them
US4025624A (en) * 1975-11-18 1977-05-24 A. H. Robins Company, Incorporated Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy
US4115587A (en) * 1976-02-04 1978-09-19 A. H. Robins Company, Inc. Fatty acid amides of norfenfluramine and compositions and methods thereof
US4237165A (en) * 1976-06-04 1980-12-02 Science Union Et Cie Treatment of carbohydrate metabolism disorders
FR2508442A1 (fr) * 1981-06-30 1982-12-31 Sanofi Sa Procede de preparation d'ethylamines b-cyclo-substituees et produits ainsi obtenus
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4857553A (en) * 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
EP0386117B1 (de) * 1987-10-22 1999-01-07 Massachusetts Institute Of Technology Behandlung des prämenstruellen oder späten lutealsphase-syndroms
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
US5587398A (en) 1996-12-24
DE69520430T2 (de) 2001-10-18
GR3036072T3 (en) 2001-09-28
JP3839049B2 (ja) 2006-11-01
HK1014671A1 (en) 1999-09-30
DE69520430D1 (de) 2001-04-26
DK0762877T3 (da) 2001-07-16
ES2157330T3 (es) 2001-08-16
CA2191996A1 (en) 1995-12-14
JPH10501239A (ja) 1998-02-03
AU2695095A (en) 1996-01-04
PT762877E (pt) 2001-08-30
US6313175B1 (en) 2001-11-06
WO1995033455A1 (en) 1995-12-14
EP0762877B1 (de) 2001-03-21
AU707142B2 (en) 1999-07-01
EP0762877A1 (de) 1997-03-19

Similar Documents

Publication Publication Date Title
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
NO933171L (no) Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
BG102202A (en) Enantiomer and ipratropiumbromide with extended effect
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
EA200500782A1 (ru) Лечение геморрагического шока
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1543158A4 (de) Regulierte aptamer-therapeutika
TR199700956T1 (xx) Indazolkarboksamidler.
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
EP1152760A4 (de) Verwendung von 4-aminopyridin zur behandlung von peripheralen neuropathien
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
TR199901385T2 (xx) Piperidin t�revleri.
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
UA43258A (uk) Спосіб лікування онкологичних хвороб

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee